Results 31 to 40 of about 8,219 (198)

Positive Affect is Associated with Better Physical Function in Early Rheumatoid Arthritis

Arthritis Care &Research, Accepted Article.
Objective This study examined the association between positive affect and physical function in individuals with early rheumatoid arthritis (RA). Methods We analyzed baseline data from 129 adults with early RA (persistent joint symptoms for ≤ 24 months) and active disease enrolled in the Central Pain in RA 2 (CPIRA‐2) study.
Burcu Aydemir, Jing Song, Lutfiyya N. Muhammad, Wendy Marder, Kevin Deane, Clifton Bingham, Lisa A. Mandl, Robert Edwards, Judith T. Moskowitz, Yvonne C. Lee   +9 more
wiley   +1 more source

Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials

Rheumatology and Therapy
Introduction This integrated analysis of the phase 2/3 and phase 3 SELECT trials describes the safety profile of upadacitinib, an oral Janus kinase inhibitor, for up to 5 years of exposure across psoriatic arthritis (PsA), ankylosing spondylitis (AS ...
Gerd R. Burmester, Jayne Stigler, Andrea Rubbert-Roth, Yoshiya Tanaka, Valderilio F. Azevedo, Derek Coombs, Ivan Lagunes, Ralph Lippe, Peter Wung, Lianne S. Gensler   +9 more
doaj   +1 more source

Hypomethylation of GNA15 Promotes Pancreatic Ductal Adenocarcinoma Progression and Macrophage M2 Polarization via STAT3‐CXCL8 Axis

Advanced Science, EarlyView.
A schematic model summarizing GNA15's mechanism in mediating macrophage M2 polarization and Gemcitabine resistance. ABSTRACT The complexity of pancreatic ductal adenocarcinoma (PDAC) progression, coupled with the lack of effective immunotherapy, underscores the imperative to deepen our understanding of its mechanisms and identify suitable immune ...
Weihui Guo, Zhenyuan Qian, Lei Wang, Weilang Xu, Yuxin Weng, Kai Jiang, Zaiyuan Ye, Ji Xu, Guangyuan Song   +8 more
wiley   +1 more source

Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study

RMD Open
Objective To evaluate the efficacy and safety of upadacitinib over 5 years among patients with rheumatoid arthritis (RA) in a long-term extension (LTE) of the SELECT-BEYOND phase 3 trial.Methods Patients refractory to ≥1 biological disease-modifying ...
Roy Fleischmann, Stephen Hall, Bernard Combe, Andrea Rubbert-Roth, Christina Charles-Schoeman, Nasser Khan, Heidi S Camp, Sebastian Meerwein, Kyle M Carter   +8 more
doaj   +1 more source

Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies

, 2022
BACKGROUND: Upadacitinib is a selective, reversible, Janus kinase (JAK) inhibitor with established efficacy in moderate-to-severe atopic dermatitis (AD). OBJECTIVE: Evaluate the safety of upadacitinib in patients with moderate-to-severe AD.
Silverberg, Jonathan I, Chih-ho Hong, H., Tenorio, Allan R., Thyssen, Jacob P, Thyssen, Jacob P., Hendrickson, Barbara, Chu, Alvina D., Irvine, Alan D., Silverberg, Jonathan I., Papp, Kim A., Guttman-Yassky, Emma, Paller, Amy S., Papp, Kim A, Chu, Alvina D, Tenorio, Allan R, Liu, John, Irvine, Alan D, Ladizinski, Barry, Dilley, Deanne, Paller, Amy S, Weidinger, Stephan, Hong, H Chih-Ho   +21 more
core   +1 more source

Upadacitinib Restrains the Pathogenic Fitness of CD4+ T Cells and Aberrant B Cell Programming in Optic Neuritis

Advanced Science, EarlyView.
Single‐cell profiling and functional perturbation reveal coordinated JAK1‐pSTAT3 downstream programs in optic neuritis, including MCL1‐dependent fitness of pathogenic CD4+ Tem cells and glycolysis‐linked, cholesterol‐sensitive B‐cell responses associated with RORA. Upadacitinib disrupts this reciprocal T‐B‐cell circuit and alleviates neuroinflammation,
Gengchen Jiang, Qi Jiang, Lian Han, Yue Peng, Xingyu Liu, Tong Yang, Hao Huang, Jiaying Liu, Yuan Gao, Hui Yang, Wenjun Zou, Zhaohuai Li, Wenru Su   +12 more
wiley   +1 more source

Growth analysis among adolescents with moderate-to-severe atopic dermatitis receiving upadacitinib in combination with topical corticosteroids in Japan: A case study series from a phase 3, randomized, controlled trial (Rising Up)

World Allergy Organization Journal, 2022
Background: Treatment options for adolescents with moderate-to-severe atopic dermatitis (AD) are limited. Oral corticosteroid therapies are used to treat children and adolescents with moderate-to-severe AD; however, long-term use is not recommended ...
Toshiaki Tanaka, MD, Takuya Sasaki, BA, Kimitoshi Ikeda, PhD, Jianzhong Liu, MD, Allan R. Tenorio, MD, Yukihiro Ohya, PhD   +5 more
doaj   +1 more source

Safety profile of upadacitinib in rheumatoid arthritis: Integrated analysis from the SELECT phase III clinical programme

, 2021
Objectives: This integrated analysis presents the safety profile of upadacitinib, a Janus kinase inhibitor, at 15 mg and 30 mg once daily in patients with moderately to severely active rheumatoid arthritis (RA). Methods: Treatment-emergent adverse events
Bessette, Louis, Cohen, Stanley B., Zerbini, Cristiano A. F., Burmester, Gerd R., Winthrop, Kevin L., Zhang, Ying, Hendrickson, Barbara, van Vollenhoven, Ronald F., Enejosa, Jeffrey V., Tanaka, Yoshiya, Khan, Nasser   +10 more
core   +1 more source

Essential Updates in the Surgical Management of Inflammatory Bowel Disease: Current Topics From 2024 to Mid‐2026

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Inflammatory bowel disease management has undergone a major transformation with the introduction of treat‐to‐target strategies and highly effective biologic and small‐molecule therapies. Although these advances have reduced the overall requirement for surgery, operative intervention remains essential for selected patients with ulcerative ...
Yoshiki Okita, Tadanobu Shimura, Mikio Kawamura, Yuhki Koike, Yuji Toiyama   +4 more
wiley   +1 more source

Efficacy of Upadacitinib in Patients with Atopic Dermatitis of the Head and Neck Region

Dermatology and Therapy
Introduction Head and neck atopic dermatitis (AD) is difficult to treat. We evaluated the efficacy of upadacitinib versus placebo in patients with head and neck AD in a post hoc analysis of Measure Up 1 (NCT03569293) and Measure Up 2 (NCT03607422 ...
Kilian Eyerich, Pedro Mendes-Bastos, Gregor Holzer, Vipul Jain, Norito Katoh, Paula C. Luna, Pablo Coto Segura, Michael Lane, Ayman Grada, Alvaro Moreira, Christopher G. Bunick   +10 more
doaj   +1 more source